Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15817MR)

This product GTTS-WQ15817MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000733.4; NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 3563
UniProt ID P07766; P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15817MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15073MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ14125MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ13077MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ1047MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ5004MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ9691MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ3014MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ13916MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN2477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.